Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

Vizient, Inc. released its new Spend Management Outlook representing the best estimate of the change in the price of pharmaceuticals, medical devices and supplies, capital equipment and services ...

Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, ...

This article included the chart below ... schizophrenia drug. However, as I wrote in an in-depth article in December, the company remains in a fantastic spot. After losing Humira exclusivity ...

account for 54% of total drug spending in the U.S., according to IQVIA. Humira®, STELARA® (Janssen Biotech) and SKYRIZI® (AbbVie) are projected to have the largest price increases for the ...

In last week’s Sunday Digest, I (Tom Yeung) wrote how cyclical companies are often incredible investments. Firms like copper ...

Over the last five years, the industry has traded as high as 20.70X, as low as 13.31X and at a median of 15.31X, as the chart below shows ... s blockbuster drug, Humira, are declining due to ...

Over the last five years, the industry has traded as high as 20.70X, as low as 13.31X and at a median of 15.31X, as the chart below shows ... s blockbuster drug, Humira, are declining due to ...

IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. released its new Spend Management Outlook representing the best estimate of the change in the price of pharmaceuticals, medical devices and supplies, ...

Says therapeutic portfolio ‘demonstrating very strong momentum’ into 2025. Says making “significant progress” in R&D efforts. Invest with ...